Mike Regan, Director of Research at Excelsior Equities, has published an initiation report on Trulieve Cannabis Corp (TCNNF/TRUL.CN, $8.67/C$11.71), “Undervalued on Status Quo + FCF & Upside Regulatory Catalysts: Rescheduling, Florida and Pennsylvania Adult Use” with a BUY rating and a $19.00 / C$25.60 price target.
The report is available to institutional investor clients of Excelsior Equities. To request access to the report, submit a request below.